{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:32:54Z","timestamp":1761744774597},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10585-018-9889-7","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T10:13:29Z","timestamp":1529576009000},"page":"521-533","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Metastatic gynecologic malignancies: advances in treatment and management"],"prefix":"10.1007","volume":"35","author":[{"given":"John K.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subasish","family":"Bhowmik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandeep","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Kapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"9889_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"9889_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.canep.2013.03.008","volume":"37","author":"P Wartko","year":"2013","unstructured":"Wartko P, Sherman ME, Yang HP et al (2013) Recent changes in endometrial cancer trends among menopausal-age U.S. women. Cancer Epidemiol 37:374\u2013377","journal-title":"Cancer Epidemiol"},{"key":"9889_CR3","first-page":"CD000402","volume":"8","author":"S Furness","year":"2012","unstructured":"Furness S, Roberts H, Marjoribanks J et al (2012) Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 8:CD000402","journal-title":"Cochrane Database Syst Rev"},{"key":"9889_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ctrv.2011.06.009","volume":"38","author":"J Iqbal","year":"2012","unstructured":"Iqbal J, Ginsburg OM, Wijeratne TD et al (2012) Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev 38:318\u2013328","journal-title":"Cancer Treat Rev"},{"key":"9889_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ygyno.2007.09.031","volume":"107","author":"JM Lancaster","year":"2007","unstructured":"Lancaster JM, Powell CB, Kauff ND et al (2007) Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107:159\u2013162","journal-title":"Gynecol Oncol"},{"key":"9889_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","volume":"371","author":"AG Renehan","year":"2008","unstructured":"Renehan AG, Tyson M, Egger M et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569\u2013578","journal-title":"Lancet"},{"key":"9889_CR7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s10552-010-9612-8","volume":"21","author":"AS Felix","year":"2010","unstructured":"Felix AS, Weissfeld JL, Stone RA et al (2010) Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 21:1851\u20131856","journal-title":"Cancer Causes Control"},{"key":"9889_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/GCO.0b013e3282f2b10d","volume":"20","author":"CA Hamilton","year":"2008","unstructured":"Hamilton CA, Kapp DS, Chan JK (2008) Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol 20:26\u201333","journal-title":"Curr Opin Obstet Gynecol"},{"key":"9889_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","volume":"94","author":"CA Hamilton","year":"2006","unstructured":"Hamilton CA, Cheung MK, Osann K et al (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94:642\u2013646","journal-title":"Br J Cancer"},{"key":"9889_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1097\/00006250-200504000-00056","volume":"105","author":"American College of O, Gynecologists","year":"2005","unstructured":"American College of O, Gynecologists (2005) ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 105:905\u2013918","journal-title":"Obstet Gynecol"},{"key":"9889_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","volume":"25","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Ward EM et al (2016) Global cancer incidence and mortality rates and trends\u2014an update. Cancer Epidemiol Biomarkers Prev 25:16\u201327","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9889_CR12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1158\/1055-9965.EPI-08-1186","volume":"18","author":"International Collaboration of Epidemiological Studies of Cervical C","year":"2009","unstructured":"International Collaboration of Epidemiological Studies of Cervical C (2009) Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev 18:1060\u20131069","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9889_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ijgo.2009.02.009","volume":"105","author":"S Pecorelli","year":"2009","unstructured":"Pecorelli S, Zigliani L, Odicino F (2009) Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 105:107\u2013108","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 1","key":"9889_CR14","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/S0020-7292(06)60030-1","volume":"95","author":"MA Quinn","year":"2006","unstructured":"Quinn MA, Benedet JL, Odicino F et al (2006) Carcinoma of the cervix uteri. FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S43\u2013S103","journal-title":"Int J Gynaecol Obstet"},{"key":"9889_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/aje\/kwp314","volume":"171","author":"MA Gates","year":"2010","unstructured":"Gates MA, Rosner BA, Hecht JL et al (2010) Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 171:45\u201353","journal-title":"Am J Epidemiol"},{"key":"9889_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist BM, Harrell MI, Brady MF et al (2016) Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2:482\u2013490","journal-title":"JAMA Oncol"},{"key":"9889_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ygyno.2012.10.023","volume":"128","author":"LM Stewart","year":"2013","unstructured":"Stewart LM, Holman CD, Aboagye-Sarfo P et al (2013) In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol 128:260\u2013264","journal-title":"Gynecol Oncol"},{"key":"9889_CR18","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1001\/jama.291.22.2705","volume":"291","author":"BA Goff","year":"2004","unstructured":"Goff BA, Mandel LS, Melancon CH et al (2004) Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291:2705\u20132712","journal-title":"JAMA"},{"key":"9889_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","volume":"4","author":"KR Cho","year":"2009","unstructured":"Cho KR, Shih Ie M (2009) Ovarian cancer. Annu Rev Pathol 4:287\u2013313","journal-title":"Annu Rev Pathol"},{"key":"9889_CR20","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1001\/jama.280.17.1510","volume":"280","author":"R Smith-Bindman","year":"1998","unstructured":"Smith-Bindman R, Kerlikowske K, Feldstein VA et al (1998) Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 280:1510\u20131517","journal-title":"JAMA"},{"key":"9889_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11912-016-0506-0","volume":"18","author":"IS Haldorsen","year":"2016","unstructured":"Haldorsen IS, Salvesen HB (2016) What is the best preoperative imaging for endometrial cancer? Curr Oncol Rep 18:25","journal-title":"Curr Oncol Rep"},{"key":"9889_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2214\/ajr.176.3.1760603","volume":"176","author":"LA Hardesty","year":"2001","unstructured":"Hardesty LA, Sumkin JH, Hakim C et al (2001) The ability of helical CT to preoperatively stage endometrial carcinoma. AJR Am J Roentgenol 176:603\u2013606","journal-title":"AJR Am J Roentgenol"},{"key":"9889_CR23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ygyno.2012.11.025","volume":"128","author":"SL Antonsen","year":"2013","unstructured":"Antonsen SL, Jensen LN, Loft A et al (2013) MRI, PET\/CT and ultrasound in the preoperative staging of endometrial cancer\u2014a multicenter prospective comparative study. Gynecol Oncol 128:300\u2013308","journal-title":"Gynecol Oncol"},{"key":"9889_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","volume":"18","author":"EC Rossi","year":"2017","unstructured":"Rossi EC, Kowalski LD, Scalici J et al (2017) A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 18:384\u2013392","journal-title":"Lancet Oncol"},{"key":"9889_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ygyno.2005.11.038","volume":"102","author":"NM deSouza","year":"2006","unstructured":"deSouza NM, Dina R, McIndoe GA et al (2006) Cervical cancer: value of an endovaginal coil magnetic resonance imaging technique in detecting small volume disease and assessing parametrial extension. Gynecol Oncol 102:80\u201385","journal-title":"Gynecol Oncol"},{"key":"9889_CR26","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1148\/radiol.12120315","volume":"266","author":"E Sala","year":"2013","unstructured":"Sala E, Rockall AG, Freeman SJ et al (2013) The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know. Radiology 266:717\u2013740","journal-title":"Radiology"},{"key":"9889_CR27","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1148\/rg.326125519","volume":"32","author":"SJ Freeman","year":"2012","unstructured":"Freeman SJ, Aly AM, Kataoka MY et al (2012) The revised FIGO staging system for uterine malignancies: implications for MR imaging. Radiographics 32:1805\u20131827","journal-title":"Radiographics"},{"key":"9889_CR28","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/j.1349-7006.2010.01532.x","volume":"101","author":"HJ Choi","year":"2010","unstructured":"Choi HJ, Ju W, Myung SK et al (2010) Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography\/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci 101:1471\u20131479","journal-title":"Cancer Sci"},{"key":"9889_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ctrv.2008.08.003","volume":"34","author":"N Magne","year":"2008","unstructured":"Magne N, Chargari C, Vicenzi L et al (2008) New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET. Cancer Treat Rev 34:671\u2013681","journal-title":"Cancer Treat Rev"},{"key":"9889_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S1470-2045(08)70005-6","volume":"9","author":"J Yazbek","year":"2008","unstructured":"Yazbek J, Raju SK, Ben-Nagi J et al (2008) Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomised controlled trial. Lancet Oncol 9:124\u2013131","journal-title":"Lancet Oncol"},{"key":"9889_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1148\/radiology.215.3.r00jn25761","volume":"215","author":"CM Tempany","year":"2000","unstructured":"Tempany CM, Zou KH, Silverman SG et al (2000) Staging of advanced ovarian cancer: comparison of imaging modalities\u2014report from the Radiological Diagnostic Oncology Group. Radiology 215:761\u2013767","journal-title":"Radiology"},{"key":"9889_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0098-2997(00)00007-8","volume":"21","author":"JS Bertram","year":"2000","unstructured":"Bertram JS (2000) The molecular biology of cancer. Mol Aspects Med 21:167\u2013223","journal-title":"Mol Aspects Med"},{"key":"9889_CR33","first-page":"98","volume":"8","author":"S Paget","year":"1989","unstructured":"Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8:98\u2013101","journal-title":"Cancer Metastasis Rev"},{"key":"9889_CR34","first-page":"6130","volume":"50","author":"IJ Fidler","year":"1990","unstructured":"Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50:6130\u20136138","journal-title":"Cancer Res"},{"key":"9889_CR35","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1073\/pnas.0437939100","volume":"100","author":"E Voronov","year":"2003","unstructured":"Voronov E, Shouval DS, Krelin Y et al (2003) IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100:2645\u20132650","journal-title":"Proc Natl Acad Sci USA"},{"key":"9889_CR36","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-05-2019","volume":"12","author":"JK Chan","year":"2006","unstructured":"Chan JK, Hamilton CA, Cheung MK et al (2006) Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 12:1859\u20131867","journal-title":"Clin Cancer Res"},{"key":"9889_CR37","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991\u2013998","journal-title":"Nat Immunol"},{"key":"9889_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/283139a0","volume":"283","author":"G Poste","year":"1980","unstructured":"Poste G, Fidler IJ (1980) The pathogenesis of cancer metastasis. Nature 283:139\u2013146","journal-title":"Nature"},{"key":"9889_CR39","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1046\/j.1432-0436.2002.700904.x","volume":"70","author":"IJ Fidler","year":"2002","unstructured":"Fidler IJ (2002) The organ microenvironment and cancer metastasis. Differentiation 70:498\u2013505","journal-title":"Differentiation"},{"key":"9889_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Filder","year":"2003","unstructured":"Filder IJ, Mandai M, Ikeda T et al (2003) The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited. Nat Rev Cancer 3:453","journal-title":"Nat Rev Cancer"},{"key":"9889_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc1252","volume":"4","author":"G Dranoff","year":"2004","unstructured":"Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4:11","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"9889_CR42","doi-asserted-by":"publisher","first-page":"C444","DOI":"10.1152\/ajpcell.00188.2015","volume":"309","author":"TL Yeung","year":"2015","unstructured":"Yeung TL, Leung CS, Yip KP et al (2015) Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol 309(7):C444\u2013C456","journal-title":"Am J Physiol Cell Physiol"},{"key":"9889_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2415","author":"J Phallen","year":"2017","unstructured":"Phallen J, Sausen M, Adleff V et al (2017) Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aan2415","journal-title":"Sci Transl Med"},{"key":"9889_CR44","doi-asserted-by":"publisher","first-page":"106415","DOI":"10.18632\/oncotarget.22468","volume":"8","author":"E Obermayr","year":"2017","unstructured":"Obermayr E, Bednarz-Knoll N, Orsetti B et al (2017) Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? A study of the OVCAD consortium. Oncotarget 8:106415\u2013106428","journal-title":"Oncotarget"},{"key":"9889_CR45","doi-asserted-by":"publisher","first-page":"viii40","DOI":"10.1093\/annonc\/mdx451","volume":"28","author":"BJ Monk","year":"2017","unstructured":"Monk BJ, Chan JK (2017) Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer? Ann Oncol 28:viii40\u2013viii45","journal-title":"Ann Oncol"},{"key":"9889_CR46","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trope CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943\u2013953","journal-title":"N Engl J Med"},{"key":"9889_CR47","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950\u20131955","journal-title":"N Engl J Med"},{"key":"9889_CR48","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"M Markman","year":"2001","unstructured":"Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001\u20131007","journal-title":"J Clin Oncol"},{"key":"9889_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34\u201343","journal-title":"N Engl J Med"},{"key":"9889_CR50","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","volume":"33","author":"D Tewari","year":"2015","unstructured":"Tewari D, Java JJ, Salani R et al (2015) Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 33:1460\u20131466","journal-title":"J Clin Oncol"},{"key":"9889_CR51","doi-asserted-by":"crossref","unstructured":"Walker JLBM., DiSilvestro PA, Fujiwara K, Alberts D, Zheng W, Tewari K, Cohn DE, Powell M, van Le L, Rubin S, Davidson SA, Gray HJ, Waggoner S, Myers T, Aghajanian C, Alvarez Secord A, Mannel RS (2016) A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and primary peritoneal carcinoma. In: Proceedings of the Society of Gynecologic Oncology","DOI":"10.1016\/j.ygyno.2016.04.535"},{"key":"9889_CR52","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Driel van","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230\u2013240","journal-title":"N Engl J Med"},{"key":"9889_CR53","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, Wang M, Martino S et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663\u20131671","journal-title":"N Engl J Med"},{"key":"9889_CR54","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","volume":"23","author":"MC Green","year":"2005","unstructured":"Green MC, Buzdar AU, Smith T et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983\u20135992","journal-title":"J Clin Oncol"},{"key":"9889_CR55","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"AD Seidman","year":"2008","unstructured":"Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642\u20131649","journal-title":"J Clin Oncol"},{"key":"9889_CR56","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331\u20131338","journal-title":"Lancet"},{"key":"9889_CR57","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","volume":"15","author":"S Pignata","year":"2014","unstructured":"Pignata S, Scambia G, Katsaros D et al (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15:396\u2013405","journal-title":"Lancet Oncol"},{"key":"9889_CR58","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMoa1505067","volume":"374","author":"JK Chan","year":"2016","unstructured":"Chan JK, Brady MF, Penson RT et al (2016) Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 374:738\u2013748","journal-title":"N Engl J Med"},{"key":"9889_CR59","doi-asserted-by":"publisher","first-page":"v605","DOI":"10.1093\/annonc\/mdx440.039","volume":"28","author":"ARMI Clamp","year":"2017","unstructured":"Clamp ARMI, Dean A et al (2017) ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian\/fallopian tube\/primary peritoneal carcinoma (EOC) treatment: results of primary progression-free survival (PFS) analysis. Ann Oncol 28:v605\u2013v649","journal-title":"Ann Oncol"},{"key":"9889_CR60","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","volume":"14","author":"N Katsumata","year":"2013","unstructured":"Katsumata N, Yasuda M, Isonishi S et al (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14:1020\u20131026","journal-title":"Lancet Oncol"},{"key":"9889_CR61","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496","journal-title":"N Engl J Med"},{"key":"9889_CR62","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483","journal-title":"N Engl J Med"},{"key":"9889_CR63","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S0140-6736(13)62226-6","volume":"383","author":"D Hanahan","year":"2014","unstructured":"Hanahan D (2014) Rethinking the war on cancer. Lancet 383:558\u2013563","journal-title":"Lancet"},{"key":"9889_CR64","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ et al (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779\u2013791","journal-title":"Lancet Oncol"},{"key":"9889_CR65","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302\u20131308","journal-title":"J Clin Oncol"},{"key":"9889_CR66","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Sill MW, Long HJ 3rd, et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734\u2013743","journal-title":"N Engl J Med"},{"key":"9889_CR67","unstructured":"FDA approves bevacizumab in combination with chemotherapy for ovarian cancer (2018) \n                    https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm610664.htm\n                    \n                  . Accessed 15 June 2018"},{"key":"9889_CR68","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154\u20132164","journal-title":"N Engl J Med"},{"key":"9889_CR69","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D et al (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1949\u20131961","journal-title":"Lancet"},{"key":"9889_CR70","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1158\/1078-0432.CCR-17-1337","volume":"23","author":"S Balasubramaniam","year":"2017","unstructured":"Balasubramaniam S, Beaver JA, Horton S et al (2017) FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clin Cancer Res 23:7165\u20137170","journal-title":"Clin Cancer Res"},{"key":"9889_CR71","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","volume":"140","author":"SM Domchek","year":"2016","unstructured":"Domchek SM, Aghajanian C, Shapira-Frommer R et al (2016) Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 140:199\u2013203","journal-title":"Gynecol Oncol"},{"key":"9889_CR72","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/ijms17071169","volume":"17","author":"G Mittica","year":"2016","unstructured":"Mittica G, Genta S, Aglietta M et al (2016) Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer? Int J Mol Sci 17:1169","journal-title":"Int J Mol Sci"},{"key":"9889_CR73","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4161\/onci.21335","volume":"1","author":"L Zitvogel","year":"2012","unstructured":"Zitvogel L, Kroemer G (2012) Targeting PD-1\/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1:1223\u20131225","journal-title":"Oncoimmunology"},{"key":"9889_CR74","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520","journal-title":"N Engl J Med"},{"key":"9889_CR75","unstructured":"FDA approves pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy (2018) \n                    https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm610572.htm\n                    \n                  . Accessed 15 June 2018"},{"key":"9889_CR76","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","volume":"21","author":"GC Stuart","year":"2011","unstructured":"Stuart GC, Kitchener H, Bacon M et al (2011) 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21:750\u2013755","journal-title":"Int J Gynecol Cancer"},{"key":"9889_CR77","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699\u20134707","journal-title":"J Clin Oncol"},{"key":"9889_CR78","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/bjc.2012.307","volume":"107","author":"U Wagner","year":"2012","unstructured":"Wagner U, Marth C, Largillier R et al (2012) Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107:588\u2013591","journal-title":"Br J Cancer"},{"key":"9889_CR79","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323\u20133329","journal-title":"J Clin Oncol"},{"key":"9889_CR80","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039\u20132045","journal-title":"J Clin Oncol"},{"key":"9889_CR81","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM et al (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18:75\u201387","journal-title":"Lancet Oncol"},{"key":"9889_CR82","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1274\u20131284","journal-title":"Lancet Oncol"},{"key":"9889_CR83","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852\u2013861","journal-title":"Lancet Oncol"},{"key":"9889_CR84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1006\/gyno.2002.6855","volume":"88","author":"RA Nagourney","year":"2003","unstructured":"Nagourney RA, Brewer CA, Radecki S et al (2003) Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 88:35\u201339","journal-title":"Gynecol Oncol"},{"key":"9889_CR85","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ygyno.2006.03.018","volume":"103","author":"CA Brewer","year":"2006","unstructured":"Brewer CA, Blessing JA, Nagourney RA et al (2006) Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 103:446\u2013450","journal-title":"Gynecol Oncol"},{"key":"9889_CR86","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1023\/B:DRUG.0000036690.14585.a3","volume":"22","author":"D Tewari","year":"2004","unstructured":"Tewari D, Monk BJ, Hunter M et al (2004) Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest New Drugs 22:475\u2013480","journal-title":"Invest New Drugs"},{"key":"9889_CR87","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1006\/gyno.2002.6850","volume":"88","author":"PG Rose","year":"2003","unstructured":"Rose PG, Mossbruger K, Fusco N et al (2003) Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 88:17\u201321","journal-title":"Gynecol Oncol"},{"key":"9889_CR88","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ygyno.2015.06.041","volume":"139","author":"KC Fuh","year":"2015","unstructured":"Fuh KC, Secord AA, Bevis KS et al (2015) Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecol Oncol 139:413\u2013418","journal-title":"Gynecol Oncol"},{"key":"9889_CR89","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322","journal-title":"J Clin Oncol"},{"key":"9889_CR90","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","volume":"25","author":"RA Burger","year":"2007","unstructured":"Burger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:5165\u20135171","journal-title":"J Clin Oncol"},{"key":"9889_CR91","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/14737140.2017.1398088","volume":"17","author":"G Corrado","year":"2017","unstructured":"Corrado G, Salutari V, Palluzzi E et al (2017) Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther 17:1147\u20131158","journal-title":"Expert Rev Anticancer Ther"},{"key":"9889_CR92","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","volume":"25","author":"SA Cannistra","year":"2007","unstructured":"Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180\u20135186","journal-title":"J Clin Oncol"},{"key":"9889_CR93","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40291-015-0167-y","volume":"19","author":"R Aarthy","year":"2015","unstructured":"Aarthy R, Mani S, Velusami S et al (2015) Role of circulating cell-free DNA in cancers. Mol Diagn Ther 19:339\u2013350","journal-title":"Mol Diagn Ther"},{"key":"9889_CR94","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409\u2013413","journal-title":"Science"},{"key":"9889_CR95","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T et al (2015) Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33:4015\u20134022","journal-title":"J Clin Oncol"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-018-9889-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-018-9889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-018-9889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T23:08:41Z","timestamp":1561072121000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-018-9889-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":95,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["9889"],"URL":"https:\/\/doi.org\/10.1007\/s10585-018-9889-7","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"3 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}